Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,647 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prescribing Trends for the Same Patients with Schizophrenia Over 20 Years.
Yasui-Furukori N, Kawamata Y, Sasaki T, Yokoyama S, Okayasu H, Shinozaki M, Takeuchi Y, Sato A, Ishikawa T, Komahashi-Sasaki H, Miyazaki K, Fukasawa T, Furukori H, Sugawara N, Shimoda K. Yasui-Furukori N, et al. Among authors: ishikawa t. Neuropsychiatr Dis Treat. 2023 Apr 17;19:921-928. doi: 10.2147/NDT.S390482. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 37089914 Free PMC article.
Factors associated with the initiation of laxative use in the same patients with schizophrenia over a 20-year period: Retrospective cohort study.
Kawamata Y, Sugawara N, Sasaki T, Yokoyama S, Okayasu H, Shinozaki M, Takeuchi Y, Sato A, Ishikawa T, Komahashi-Sasaki H, Miyazaki K, Fukasawa T, Furukori H, Yasui-Furukori N. Kawamata Y, et al. Among authors: ishikawa t. Neuropsychopharmacol Rep. 2024 Mar;44(1):60-66. doi: 10.1002/npr2.12378. Epub 2023 Sep 12. Neuropsychopharmacol Rep. 2024. PMID: 37698084 Free PMC article.
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, Maeda Y, Inamoto Y, Okada M, Maki A, Shimada F, Tajima T, Wroclawska M, Zeiser R, Onizuka M. Teshima T, et al. Among authors: ishikawa t. Int J Hematol. 2024 May 25. doi: 10.1007/s12185-024-03772-6. Online ahead of print. Int J Hematol. 2024. PMID: 38796666
Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: a systematic review.
Ishikawa T, Nishimura K, Okamoto N, Akamine K, Inoue N, Irabu H, Kato K, Keino H, Kojima M, Kubo H, Maruyama K, Mizuta M, Shabana K, Shimizu M, Sugita Y, Takakuwa Y, Takanashi S, Takase H, Umebayashi H, Umezawa N, Yamanishi S, Yamazaki K, Yashiro M, Yasumi T, Mori M. Ishikawa T, et al. Mod Rheumatol. 2024 May 25:roae050. doi: 10.1093/mr/roae050. Online ahead of print. Mod Rheumatol. 2024. PMID: 38795057
A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study.
Kaneko N, Loughrey CM, Smith G, Matsuda R, Hasunuma T, Mark PB, Toda M, Shinozaki M, Otani N, Kayley S, Da Silva Costa A, Martin TP, Dobi S, Saxena P, Shimamoto K, Ishikawa T, Kambayashi R, Riddell A, Elliott EB, McCarroll CS, Sakai T, Mitsuhisa Y, Hirano S, Kitai T, Kusano K, Inoue Y, Nakamura M, Kikuchi M, Toyoda S, Taguchi I, Fujiwara T, Sugiyama A, Kumagai Y, Iwata K. Kaneko N, et al. Among authors: ishikawa t. Br J Pharmacol. 2024 May 21. doi: 10.1111/bph.16379. Online ahead of print. Br J Pharmacol. 2024. PMID: 38773354
Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: a systematic review.
Nishimura K, Ishikawa T, Okamoto N, Akamine K, Inoue N, Irabu H, Kato K, Keino H, Kojima M, Kubo H, Maruyama K, Mizuta M, Shabana K, Shimizu M, Sugita Y, Takakuwa Y, Takanashi S, Takase H, Umebayashi H, Umezawa N, Yamanishi S, Yamazaki K, Yashiro M, Yasumi T, Mori M. Nishimura K, et al. Among authors: ishikawa t. Mod Rheumatol. 2024 May 16:roae046. doi: 10.1093/mr/roae046. Online ahead of print. Mod Rheumatol. 2024. PMID: 38753302
7,647 results